Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 14/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL536413 | 1.00 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973516 | 1.00 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2402213 | 1.00 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4424488 | 0.98 | FDPS (0.63) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3389 | 0.98 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4421548 | 0.96 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2282829 | 0.96 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4279500 | 0.96 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL16767406 | 0.93 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284355 | 0.93 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 993 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2201937-A1 | Formulations comprising vitamin D or derivatives thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-30 | — | — | EP | claimed |
| US-6963008-B2 | Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-08 | — | — | US | claimed |
| US-20050025807-A1 | Cured porous calcium phosphate material and uses thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2005-02-03 | — | — | US | claimed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20030203878-A1 | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | FLASHNER-BARAK MOSHE (IL) | 2003-10-30 | — | — | US | claimed |
| EP-1296657-A1 | COMPOSITION AND DOSAGE FORM FOR DELAYED GASTRIC RELEASE OF ALENDRONATE AND/OR OTHER BIS-PHOSPHONATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-02 | — | — | EP | claimed |
| US-6476006-B2 | COMPACT FORM FOR ORAL ADMINISTERING; BONE DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-11-05 | — | — | US | claimed |
| US-20020015733-A1 | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | TEVA PHARMACEUTICAL USA, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002000204-A1 | COMPOSITION AND DOSAGE FORM FOR DELAYED GASTRIC RELEASE OF ALENDRONATE AND/OR OTHER BIS-PHOSPHONATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-03 | — | — | WO | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-6281381-B1 | CRYSTAL STRUCTURE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-28 | — | — | US | disclosed |
| EP-1107974-A1 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-06-20 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001032637-A1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000012517-A9 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000012517-A1 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | FDPS 1537/4885PDE3A 3361/4885LMNA 3858/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | FDPS 3704/4885PDE3A 3900/4885LMNA 4300/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | FDPS 4795/4885PDE3A 4045/4885LMNA 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.